Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2016

View Archived Issues

Lycera studies LYC-55716 in phase I/IIa trial in locally advanced or metastatic cancer

Targeting the NK-1 receptor has antispastic effects after chronic spinal injury

PF-06648671 reduces cerebrospinal fluid amyloid-beta after single and multiple doses

ROSGard demonstrates renal protective effect during radiation therapy

Amgen patents appelin receptor agonists

EMA validates Oxervate MAA for neurotrophic keratitis

BioMarin Pharmaceutical begins phase III study of vosoritide in achondroplasia

Flexion Therapeutics submits NDA to FDA for Zilretta

Metabolite profiling shows anandamide is linked to nonalcoholic steatohepatitis in obesity

Purdue Pharma and Exicure enter collaboration agreement in psoriasis

Achaogen reports favorable results from phase III trials of plazomicin

University of Michigan discloses cyclic peptides

Idenix Pharmaceuticals describes prodrugs of gemcitabine

Almirall and Nuevolution to jointly develop RORgammat inhibitors

Pharmascience develops TEC kinase inhibitors

Eiger BioPharmaceuticals reports interim results from phase II study of exendin 9-39 in PBH

First preclinical data for LOXO-195

Novel model reveals roles of Iroquois homeobox proteins in left ventricular noncompaction

M-DGN-549: a new ADC for cancer

Preclinical data on TPC-144 for the treatment of AML and SCLC

Phase II data show efficacy of pembrolizumab for cutaneous T-cell lymphomas

Bayer and Versant Ventures establish BlueRock Therapeutics

Phase IIa results further support potential of RedHill Biopharma's RHB-104 in multiple sclerosis

Defymed collaborates with Semma Therapeutics to develop innovative treatment for type 1 diabetes

Revance reports interim data from phase II study of RT-002 in cervical dystonia

Arimoclomol shows safety and efficacy in phase II trial in patients with ALS due to SOD1 mutation

IGNITE Immunotherapy launches, will focus on oncolytic virus vaccines with lead investor, Pfizer

Astellas Pharma transfers Qutenza to Grunenthal

MeiraGTx expands pipeline with program targeting retromer

EC grants marketing authorization to Arzerra in combination with FC for CLL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...